
1. General Information
Bevacirel 400 mg Injection is an oncology medicine containing bevacizumab. It is used under specialist medical supervision for certain advanced or metastatic cancers. Bevacizumab works by targeting VEGF, a protein involved in the formation of new blood vessels that can support tumor growth.
Product: Bevacirel 400 mg/16 mL Injection
Active ingredient: Bevacizumab
Dosage form: Concentrate/solution for intravenous infusion
Strength: 400 mg/16 mL
Therapeutic category: Antineoplastic / anti-angiogenic monoclonal antibody
2. Product Information
Bevacirel 400 mg/16 mL is supplied as a sterile solution intended for IV infusion by a qualified healthcare professional. The exact dose and treatment interval depend on the cancer type, treatment protocol, body weight, kidney/liver status, and other medicines being used.
It should be handled and administered according to the product information and the oncologist's instructions.
3. Uses of Bevacirel 400 mg
Bevacizumab-containing medicines may be used as part of treatment protocols for several cancers, including:
- Metastatic colorectal cancer
- Non-squamous non-small-cell lung cancer
- Metastatic renal cell carcinoma
- Glioblastoma
- Persistent, recurrent, or metastatic cervical cancer
- Certain epithelial ovarian, fallopian-tube, or primary peritoneal cancers
The approved indications and combinations can differ by country and regulatory authority.
4. Benefits of This Medicine
Potential therapeutic benefits of bevacizumab include:
- Helps inhibit the formation of new blood vessels supplying tumors.
- May slow tumor growth and disease progression.
- Can be combined with chemotherapy or other anticancer treatments when clinically appropriate.
- Provides a targeted anti-angiogenic approach to cancer treatment.
Important: Benefits vary according to the cancer type, stage, treatment combination, and individual patient response.
5. Side Effects of Bevacirel 400 mg
Bevacizumab can cause side effects ranging from mild to potentially serious. Important adverse effects include:
- High blood pressure
- Protein in the urine
- Bleeding or hemorrhage
- Blood clots
- Delayed wound healing
- Gastrointestinal perforation
- Infusion-related reactions
- Kidney-related complications
- Rare neurological complications
Serious complications require prompt medical assessment.
6. Common Side Effects
Frequently reported adverse effects of bevacizumab include:
- Headache
- High blood pressure
- Nosebleeds
- Proteinuria
- Fatigue
- Back or muscle pain
- Taste changes
- Dry skin
- Runny or stuffy nose
- Minor bleeding
- Changes in tearing
Patients should tell their healthcare professional if side effects become severe, persistent, or unusual.
7. How to Use Bevacirel 400 mg
Bevacirel 400 mg is not a self-administered injection. It is administered as an intravenous infusion by a healthcare professional, generally in a hospital, clinic, or appropriate oncology facility.
The oncologist determines:
- Dose
- Dilution and infusion procedure
- Treatment frequency
- Duration of treatment
- Whether it should be combined with chemotherapy or another anticancer medicine
The patient should not change the dose or treatment schedule without medical advice.
8. How This Medicine Works
Bevacizumab targets vascular endothelial growth factor (VEGF). VEGF promotes the formation of new blood vessels, a process known as angiogenesis.
By binding to VEGF, bevacizumab reduces VEGF-mediated signaling and can inhibit the development of new blood vessels that tumors use to obtain nutrients and oxygen. This can help slow tumor growth and progression.
9. Safety Advice
Before treatment, patients should inform their doctor about:
- Previous allergic reactions to bevacizumab or other medicines
- High blood pressure
- Bleeding or blood-clotting problems
- Recent or planned surgery
- Previous gastrointestinal problems
- Kidney problems or protein in the urine
- Current chemotherapy, anticoagulants, or other medicines
- Pregnancy or plans to become pregnant
Bevacizumab can affect wound healing, and special precautions are required around surgery. MedlinePlus notes that doctors may stop treatment before surgery and wait for adequate healing afterward.
During infusion, symptoms such as difficulty breathing, chest pain, dizziness, chills, rash, itching, or flushing should be reported immediately to the medical team.
Storage: Follow the manufacturer's approved storage instructions. Product information for BevaciRel identifies the product as a sterile infusion preparation; storage conditions should be confirmed from the current package insert and pharmacy/wholesaler documentation.
10. Frequently Asked Questions (FAQs)
Q1. What is Bevacirel 400 mg Injection?
Bevacirel 400 mg/16 mL is a bevacizumab-containing anticancer injection used as part of treatment protocols for certain cancers.
Q2. What is the active ingredient in Bevacirel?
The active ingredient is bevacizumab.
Q3. How is Bevacirel 400 mg administered?
It is administered through an intravenous infusion by a healthcare professional.
Q4. Is Bevacirel a chemotherapy medicine?
Bevacizumab is a targeted biological/anti-angiogenic therapy rather than a conventional cytotoxic chemotherapy drug. It may nevertheless be administered in combination with chemotherapy.
Q5. Can Bevacirel 400 mg be used for all cancers?
No. Its use depends on the cancer type, stage, treatment protocol, regulatory approval, and the treating oncologist's assessment.
Q6. What are the major side effects?
High blood pressure, bleeding, proteinuria, blood clots, impaired wound healing, gastrointestinal perforation, and infusion reactions are among the important potential adverse effects.
Q7. Can patients administer Bevacirel at home?
No. It should be administered by trained healthcare professionals in an appropriate medical setting.
Q8. Is Bevacirel 400 mg the same as other bevacizumab 400 mg injections?
Products containing the same active ingredient and strength may be therapeutic alternatives in particular circumstances, but interchangeability depends on regulatory approval, product characteristics, and the prescribing physician's decision.
11. Substitute / Alternative Products
Possible bevacizumab-containing alternatives include products such as:
- Avastin (bevacizumab)
- Bevatas 400 mg
- Abevmy 400 mg
- Cizumab 400 mg
- Bryxta 400 mg
- Krabeva 400 mg
These are not automatically interchangeable for every patient. The appropriate product should be selected by a qualified healthcare professional based on indication, regulatory status, availability, and clinical requirements. BevaciRel itself is documented as a bevacizumab product in 100 mg/4 mL and 400 mg/16 mL presentations.
12. SEO & B2B Keywords
For Phoenix Exim, Nagpur, India, you can use keywords such as:
- Bevacirel 400mg injection supplier India
- Bevacirel 400mg injection exporter from India
- Bevacirel 400mg/16ml injection exporter
- Bevacirel 400mg wholesale supplier India
- Bevacizumab 400mg injection supplier
- Bevacizumab 400mg injection exporter India
- Bevacizumab 400mg/16ml wholesale supplier
- Bevacirel 400mg injection pharmaceutical exporter
- Bevacirel 400mg oncology medicine supplier
- Bevacirel 400mg cancer medicine exporter
- Bevacizumab injection B2B supplier India
- Bevacizumab oncology medicine exporter Nagpur
- Bevacirel 400mg injection supplier USA
- Bevacirel 400mg injection supplier UK
- Bevacirel 400mg injection supplier Australia
- Bevacirel 400mg injection supplier Canada
- Bevacirel 400mg injection supplier Singapore
- Bevacirel 400mg injection supplier South Korea
- Bevacirel 400mg injection supplier UAE
- Bevacirel 400mg injection international pharma supplier
- Bevacizumab 400mg oncology injection exporter India
- Bevacirel 400mg/16ml pharmaceutical supplier
- Bevacirel 400mg injection bulk supplier India
- Bevacirel 400mg injection wholesale exporter Nagpur
- Phoenix Exim Bevacirel 400mg supplier
- Phoenix Exim Bevacizumab injection exporter
- Bevacirel 400mg international medicine supplier
- Bevacirel 400mg anti cancer injection supplier
- Bevacizumab 400mg targeted cancer therapy supplier
- Bevacirel 400mg pharma export supplier India
Keywords







